Texas Permanent School Fund Corp Buys 5,080 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Texas Permanent School Fund Corp grew its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 28.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,715 shares of the company’s stock after acquiring an additional 5,080 shares during the period. Texas Permanent School Fund Corp owned 0.08% of Fulgent Genetics worth $446,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Quest Partners LLC grew its holdings in shares of Fulgent Genetics by 26,055.9% in the 2nd quarter. Quest Partners LLC now owns 17,786 shares of the company’s stock valued at $349,000 after acquiring an additional 17,718 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Fulgent Genetics by 593.5% in the 2nd quarter. Acadian Asset Management LLC now owns 62,724 shares of the company’s stock valued at $1,227,000 after acquiring an additional 53,680 shares in the last quarter. Asset Dedication LLC bought a new position in shares of Fulgent Genetics in the 2nd quarter valued at about $33,000. Acuitas Investments LLC bought a new position in shares of Fulgent Genetics in the 2nd quarter valued at about $962,000. Finally, Rhumbline Advisers grew its holdings in shares of Fulgent Genetics by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock valued at $1,338,000 after acquiring an additional 637 shares in the last quarter. Institutional investors own 48.06% of the company’s stock.

Insider Buying and Selling at Fulgent Genetics

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the sale, the chief executive officer now owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 4,324 shares of company stock valued at $98,717 in the last quarter. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT opened at $21.98 on Friday. Fulgent Genetics, Inc. has a 52-week low of $18.91 and a 52-week high of $30.68. The company has a market capitalization of $657.73 million, a P/E ratio of -3.95 and a beta of 1.50. The company has a 50-day simple moving average of $22.89 and a 200 day simple moving average of $21.70.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The company had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same period last year, the firm posted ($0.33) earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. As a group, equities analysts forecast that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.